RxDoctor Payments Data

James Rusch, MD

Psychiatry · Gulfport, MSNPI 1780618686

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 61.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,011 and has fallen 93.2% since, to $137 in 2025.

$3,122in general payments, 2019–2025

Across 28 payments — averaging $111.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$602
  • Neurocrine Biosciences, Inc.$153
  • Alkermes, Inc.$138
  • Johnson & Johnson$114
  • Vanda Pharmaceuticals Inc.$59
  • plus $123 from 4 others

What the payments were for

  • Speaking & faculty fees$1,58651%
  • Travel & lodging$201%
  • Food & beverage$1,51649%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,122 in reported general payments places this provider in the 80th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$6,069
Medicare patients
28
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PerserisRisperidone11$30,780
Mirtazapine14$262
Olanzapine20$209
Benztropine Mesylate13$84
Trazodone Hcl14$51
Buspirone Hcl11$47
Fluoxetine Hcl13$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Perseris$24$30,78011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →